Page values for "Valsartan"
Appearance
"Medicines" values
1 row is stored for this page| Field | Field type | Value |
|---|---|---|
| generic | String | Valsartan |
| brand | String | Diovan; Entresto (in fixed-dose combination with sacubitril) |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blocker (ARB)]] • [[:Category:Antihypertensives|Antihypertensive]] |
| mechanism | String | '"`UNIQ--vote-000004C8-QINU`"' Largely hepatically cleared (~80% biliary); no active metabolite. Sacubitril-valsartan (Entresto) combines an ARB with neprilysin inhibition for HFrEF and was a notable advance over the ARB-alone trial (PARADIGM-HF, 2014)'"`UNIQ--ref-000004C9-QINU`"'. |
| uses | String | '"`UNIQ--vote-000004CA-QINU`"', '"`UNIQ--vote-000004CB-QINU`"', '"`UNIQ--vote-000004CC-QINU`"' |
| starting_dose | String | 80-160 mg PO once daily (40 mg BID in HFrEF, titrating up to 160 mg BID) |
| preparations | String | 40, 80, 160, 320 mg tablets; oral suspension |
| fda_max | String | 320 mg/d (hypertension); 320 mg/d (HF) |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | BP effect 2 hours; max at 4-6 weeks |
| duration | String | 24 hours |
| halflife | String | ~6 hours'"`UNIQ--ref-000004CD-QINU`"' |
| bioavailability | String | ~25% (oral; food reduces absorption ~40%)'"`UNIQ--ref-000004CE-QINU`"' |
| pregnancy | String | '''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-000004CF-QINU`"' |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |